Immunotherapeutics against cancer and infectious diseases

ISA Pharmaceuticals B.V. is developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections.

News

February 26, 2015
ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugates
November 27, 2014
Publication in Nature Supports ISA Pharmaceuticals´ Synthetic Long Peptide Immunotherapeutic Approach to Treat Cancer

Events

March 3 – 4, 2015
8th Annual European Life Science CEO Forum & Exhibition
March 9 – 11, 2015
BIO-Europe Spring

Latest Publications

September 22, 2013
ECCO-ESMO
Prior chemotherapy improves the immune response to a synthetic long peptide cancer vaccine against HPV16: a phase I toxicity-immunogenicity study in cervical cancer patients

More news

More events

More publications

Loading Quotes...